NCT07098091

Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of YD0293 in Healthy Subjects

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Single and Multiple Doses of YD0293 Tablets in Healthy Subjects

• Status: Enrolling By Invitation
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 78 (estimated)
• Sponsor: Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

This study is a single-center, single- and multiple-dose escalating study with a food-effect component, designed to evaluate the safety, tolerability, and pharmacokinetic (PK) characteristics of YD0293 tablets following a single oral dose in healthy subjects, as well as the effect of food on PK parameters and the potential effect on the QT interval. The study also aims to assess the safety, tolerability, and PK profile of YD0293 tablets following multiple oral doses in healthy subjects.

Conditions

• Healthy Participants

Interventions

Type	Name	Description
DRUG	YD0293	YD0293 tablet for oral administration
DRUG	YD0293 placebo	YD0293 placebo tablet for oral administration

Timeline

• Start date: 2025-02-26
• Primary completion: 2025-12-31
• Completion: 2025-12-31
• First posted: 2025-08-01
• Last updated: 2025-08-17

Locations

1 site across 1 country: China